3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
149
Breast Neoplasms
87
Colorectal Neoplasms
64
Neoplasms
53
Pancreatic Neoplasms
52
Lung Neoplasms
49
Neoplasm Metastasis
45
Stomach Neoplasms
43
Ovarian Neoplasms
42
Rectal Neoplasms
41
Esophageal Squamous Cell Carcinoma
34
Esophageal Neoplasms
33
Squamous Cell Carcinoma of Head and Neck
30
Head and Neck Neoplasms
30
Leukemia, Myeloid, Acute
28
Recurrence
24
Triple Negative Breast Neoplasms
22
Precursor Cell Lymphoblastic Leukemia-Lymphoma
22
Glioblastoma
21
Uterine Cervical Neoplasms
20
Small Cell Lung Carcinoma
20
Nasopharyngeal Carcinoma
20
Fallopian Tube Neoplasms
19
Lymphoma, Non-Hodgkin
18
Lymphoma
18
Colonic Neoplasms
17
Prostatic Neoplasms
16
Leukemia
15
Carcinoma, Ovarian Epithelial
15
Melanoma
14
Interventions
pembrolizumab
92
Gemcitabine
55
Nivolumab
49
Cisplatin
38
atezolizumab
31
Carboplatin
30
avelumab
25
enfortumab vedotin
24
Docetaxel
23
Magnetic Resonance Spectroscopy
18
Ipilimumab
17
Paclitaxel
16
Mitomycin
15
Specimen Handling
14
durvalumab
11
toripalimab
10
sacituzumab govitecan
10
Pemetrexed
10
cabozantinib
9
Taxes
8
vinflunine
7
Cyclophosphamide
7
tislelizumab
6
Injections
6
Bevacizumab
6
pemigatinib
5
fludarabine
5
disitamab vedotin
5
Standard of Care
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Transitional Cell
×
Drug Therapy
×
Clear all
NCT03410693
2022-09-28
FORT-1
Bayer
Phase 2/3
Completed
175 enrolled
19 charts